Friday 6 November 2026 Export ADPT’s income statement to Excel — free account

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.

Revenue: −10.7%
EPS: −66.7%
Free cash flow: +201.9%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

27.17 0.34 +1.27%

Follow ADPT

Alert me

Market cap: $4.3B
P/E: 0.0×
Fwd P/E: −49.4×
Dividend yield: —
F-score: 6/9
Altman Z: 2.08
Beneish M: −2.44
Dividend safety: n/a

Overview

Adaptive Biotechnologies Corporation (ADPT) Price to free cash flow

Alert me on Price to free cash flow

Adaptive Biotechnologies Corporation has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 18.9× (October 2019) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ADPT/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Adaptive Biotechnologies Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ADPT/metrics/price-to-free-cash-flow">Adaptive Biotechnologies Corporation (ADPT) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	10.7×	384.07%
FY2018	2.2×	0.00%
FY2017	2.2×	—

Period	Price to free cash flow	Change
Sep 2026	0.0×	—
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
29 more quarters	Free account

Against its own ten years

Low 0.0× High 18.9×

Ten-year median 0.0×

Current reading's percentile 90

Company	Price to free cash flow
WGS GeneDx Holdings Corp. compare	n/m
NEO NeoGenomics, Inc. compare	n/m
GRAL GRAIL, Inc. compare	n/m
ADPT Adaptive Biotechnologies Corporation	n/m
VCYT Veracyte, Inc. compare	12.0×
SHC Sotera Health Company compare	33.5×
CDNA CareDx, Inc. compare	68.9×
BLLN BillionToOne, Inc. compare	156×
RDNT RadNet, Inc. compare	189×
Diagnostics & Research industry median	33.5×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Adaptive Biotechnologies Corporation (ADPT) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ADPT

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ADPT

Stockrow Weekly